Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 937-942

  Lau, Yau Yi ^a   Chen, Yung Hsiang ^a   Liu, Tong Tong ^a   Li, Cheng ^a   Cui, Xiaoming ^a   White, Ronald E ^a   Cheng, K C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BRETYLIUM; CAFFEINE; CHLOROTHIAZIDE; CHLORPROMAZINE; CYCLOSPORIN; DESIPRAMINE; DIAZEPAM; FLUOXETINE; GANCICLOVIR; IMIPRAMINE; LORAZEPAM; METOCLOPRAMIDE; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; OXAZEPAM; PIRENZEPINE; PROPRANOLOL; SILDENAFIL; TERBUTALINE; THEOPHYLLINE; TIMOLOL; VERAPAMIL;

APPARATUS; AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; CELL STRAIN CACO 2; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; EVALUATION; FILTER; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HYBRID CELL; IN VITRO STUDY; LIVER CELL; PRIORITY JOURNAL; TIGHT JUNCTION; TIME;

ABSORPTION; ADMINISTRATION, ORAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; HYBRID CELLS; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS;

EID: 4143057306     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Anderson JL, Patterson E, Wagner JG, Stewart JR, Behm HL, and Lucchesi BR (1980) Oral and intravenous bretylium disposition. Clin Pharmacol Ther 28:468-478.
2. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
3. Benet LZ, Oie S, and Schwartz JB (1996) Design and optimization of dosage regimens: pharmacokinetics data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Gilman AG, Hardman JG, Limbard LE, Molinoff PB, and Ruddon RW eds), 9th ed, pp 1707-1792, McGraw Hill, New York.
4. Chiou WL and Barve A (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res (NY) 15:1792-1795.
5. Ciraulo DA, Barnhill IG, and Jaffe JR (1999) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43:509-518.
6. Cox KA, White RE, and Korfmacher WA (2002) Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches. Comb Chem High Throughput Screen 5:29-37.
7. Eichelbaum M, Mikus G, and Vogelgesang B (1984) Pharmacokinetics of (+)-, (-)- and (±)-verapamil after intravenous administration. Br J Clin Pharmacol 17:453-458.
8. Greenblatt DJ (1981) Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 6:89-105.
9. Krakamp B, Tanswell P, Vogel H, and Bozler G (1989) Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. Eur J Clin Pharmacol 36:75-78.
10. Krishna G, Chen K, Lin CC, and Nomeir A (2001) Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 222:77-89.
11. Lau YY, Sapidou E, Cui X, White RE, and Cheng KC (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454.
12. Lavé T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, and Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res (NY) 14:152-155.
13. Mahmood I (2000) Can absolute oral bioavailability in human be predicted from animals? A comparison of allometry and different indirect methods. Drug Metab Drug Interact 16:143-155.
14. Mandagere AK, Thompson TN, and Hwang KK (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311.
15. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
16. Nyberg L (1984) Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis 134:149-160.
17. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
18. Prentis RA, Lis Y, and Walker SR (1988) Pharmaceutical innovation by the seven UK-owned companies (1964-1985). Br J Clin Pharmacol 25:387-396.
19. Schneider G, Coassolo P, and Lavé T (1999) Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J Med Chem 42:5072-5076.
20. Stoner CL, Cleton A, Johnson K, Oh DM, Hallak H, Brodfuehrer J, Surendran N, and Han HK (2004) Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Int J Pharm 269:241-249.
21. Thummel KE and Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman 's The Pharmacological Basis of Therapeutics (Hardman JG, Limbard LE, and Gilman AG eds), 10th ed, pp 1917-2023, McGraw Hill, New York.
22. Transwell P, Hofgartner R, Bozler G, Giesler H, Allmendinger G, and Schmid E (1990) Absolute bioavailability of pirenzepine in intensive care patients. Eur J Clin Pharmacol 38:265-268.
23. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, and Wright PA (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:297-310.
24. Yazdanian M, Glynn SL, Wright JL, and Hawi A (1998) Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res (NY) 15:1490-1494.
25. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res (NY) 14:763-766.